Government Affairs
Refine search
Pharmaceutical
Fewer new innovative medicines, and in fact with a delay of almost two years from their approval by the European Medicines Agency (EMA), are coming to Greece, as demonstrated by the Association of Pharmaceutical Companies of Greece (SFEE) in a press conference held to present two studies concerning Greek patients' access to new, innovative treatments. 1 June 2026
Pharmaceutical
The Pharmaceutical Research and Manufacturers of America has used National Cancer Research Month to argue that US cancer research leadership could weaken if pricing and reimbursement policies reduce incentives for drug development. 29 May 2026
Pharmaceutical
The European Parliament and European Union (EU) member states have reached a provisional agreement on the Critical Medicines Act (CMA), a major legislative initiative designed to strengthen medicine supply chains and reduce dependence on overseas manufacturing. 22 May 2026
Pharmaceutical
Jeffery Taubenberger, the acting director of the US National Institute of Allergy and Infectious Diseases (NIAID), has stepped down from the role, according to reports citing congressional Democrats and sources familiar with the matter. 22 May 2026
Biotechnology
A new national framework designed to strengthen the delivery of advanced therapy clinical trials across the UK has been launched by the Advanced Therapy Treatment Centre (ATTC) network, as the country seeks to reinforce its position in the fast-growing cell and gene therapy sector. 20 May 2026
Pharmaceutical
Northern Ireland’s life sciences industry is set to benefit from closer collaboration with the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), it was announced Wednesday. 14 May 2026
Pharmaceutical
India has once again been placed on the Priority Watch List in the 2026 Special 301 Report released by the Office of the United States Trade Representative (USTR). 13 May 2026
Pharmaceutical
The Wall Street Journal Editorial Board is once again raising concerns about the USA’s federal 340B drug pricing program – this time questioning whether the program is benefiting patients at all. 12 May 2026
Pharmaceutical
For the first time, Swedish pharma trade group Lif launched its own program track at Vitalis. Together with the Swedish Medical Products Agency, SweTrial and Swedish Medtech, the focus was on how Sweden can strengthen its position as an attractive clinical trial country. 11 May 2026
Biosimilars
Industry group Medicines for Europe has urged policymakers to strengthen support for biosimilar medicines, arguing that wider uptake could improve patient access to biologic therapies while reinforcing Europe’s pharmaceutical resilience. 7 May 2026
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027. 7 May 2026
Pharmaceutical
As Europe strives to compete globally in life sciences, predictable and robust IP incentives will determine whether tomorrow’s breakthroughs are developed here or elsewhere, says the European Federation of Pharmaceutical Industries and Associations (EFPIA). 27 April 2026
Pharmaceutical
India’s Central Drugs Standard Control Organization (CDSCO) and Brazil’s National Health Surveillance Agency (ANVISA), have established a framework to align regulatory practices. 27 April 2026
Pharmaceutical
Among significant news last week, Denmark’s Novo Nordisk presented positive results for its sickle cell disease candidate etavopivat. Eli Lilly revealed an up to $7 billion deal to acquire Kelonia Therapeutics and its gene therapy KLN-1010. The US Centers for Medicaid and Medicare Services (CMS) has extended the GLP-1 Bridge program for obesity medicines as insurers hold back. US biopharma Grace Therapeutics suffered a setback as the US Food and Drug Administration (FDA) issued a complete response letter (CRL) on the company’s new drug application (NDA) for GTx-104, which is being developed for aneurysmal subarachnoid hemorrhage (aSAH). 26 April 2026
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim’s Indian subsidiary and India’s National Institute of Pharmaceutical Education and Research (NIPER) have signed a five year memorandum of understanding (MoU) to advance pharmaceutical research, education, and innovation in eastern India. 25 April 2026
Biotechnology
Over the decades, Germany’s Bayer has played as big a part as any company in the discovery and development of innovative medicines to treat patients around the world. 24 April 2026
Pharmaceutical
The US government is set to bear the financial burden of covering blockbuster obesity medicines for Medicare beneficiaries, after private insurers balked at participating in a planned long-term payment model. 22 April 2026
Pharmaceutical
As US states debate new proposals to regulate prescription drug prices - such as prescription drug boards or referencing federal or foreign pricing - it’s critical to examine the real-world consequences of government-set prices. 22 April 2026
Pharmaceutical
Russia plans to increase public procurements of anti-cancer drugs that will be part of a new national project, which aims to ensure two-thirds of cancer patients survive five years or more after diagnosis with cancer by 2030, reports The Pharma Letter’s local correspondent. 20 April 2026
Pharmaceutical
Swiss industry group Interpharma has called for the country to maintain and expand its bilateral framework with the European Union, warning that political proposals affecting migration could disrupt the pharmaceutical sector. 20 April 2026
Pharmaceutical
The US Federal Trade Commission has hailed what it calls a ‘landmark settlement’ with one of the nation’s largest pharmacy benefit managers (PBMs), Express Scripts, and its affiliated entities. 5 February 2026
Pharmaceutical
The USA’s Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR), in collaboration with VITAL, has opened solicitations for the SMART Antiviral Prize, a $100 million initiative supporting development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the Togaviridae and Flaviviridae families. 4 February 2026
Pharmaceutical
The US Department of Health and Human Services (HHS) has sharply expanded its use of artificial intelligence, listing around 450 AI use cases across the department in a newly published fiscal 2025 inventory. 4 February 2026
Generics
US generics lobby the Association for Accessible Medicines (AAM) has welcomed passage of Q1/Q2 provisions in recent US funding legislation, arguing they will speed access to lower-cost medicines. 4 February 2026
Pharmaceutical
The UK and Japan have announced a major package of science and technology collaborations, it has been announced. 3 February 2026
Pharmaceutical
The India-European Union (EU) Free Trade Agreement (FTA) represents a significant opportunity for India's pharmaceutical sector, opening doors to a $572.3 billion market while reinforcing India's global healthcare leadership, reports The Pharma Letter’s India correspondent. 2 February 2026
Pharmaceutical
The USA’s Centers for Medicare & Medicaid Services (CMS) just dropped the next 15 drugs that will face government set prices in 2028 under the Inflation Reduction Act, causing a reaction from trade group Pharmaceutical Research and Manufacturers of America (PhRMA). 29 January 2026
Pharmaceutical
British pharma major AstraZeneca said it will invest $15 billion in China through 2030 to expand medicines manufacturing and R&D, underlining the market’s importance as its second-largest globally and a growing engine of revenue. 29 January 2026
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) has announced the selection of 15 high-cost prescription medicines covered under Medicare Part D and—for the first time—those payable under Medicare Part B, for the third cycle of the Medicare Drug Price Negotiation Program. 28 January 2026
Pharmaceutical
The Centers for Medicare & Medicaid Services (CMS) is seeking public input on ways to strengthen domestic supply chains for personal protective equipment and essential medicines, as concerns persist over the USA’s heavy reliance on foreign manufacturing. 27 January 2026
Pharmaceutical
The Irish Pharmaceutical Healthcare Association (IPHA) has welcomed the new four-year framework agreement, expressing confidence that it will allow more innovative medicines to reach patients faster, and describing it as a positive step in supporting the life sciences industry in Ireland. 26 January 2026
Pharmaceutical
A Danish pharma trade group is calling for a formal evaluation of Denmark’s rules on mandatory stockpiles of “critical” medicines, arguing the requirements have increased administrative burden while leaving unanswered whether the policy has improved supply security for patients. 26 January 2026
Pharmaceutical
The Russian government plans to provide additional funding for the establishment of a full production cycle of a number of vaccines within the country this year and to ensure their stable supplies for state needs, The Pharma Letter’s local correspondent reports. 26 January 2026
Biotechnology
Belgian biopharma UCB has announced a capital boost from the UK government’s Life Sciences Innovative Manufacturing Fund (LSIMF), to support its ongoing investment in R&D in the country. 23 January 2026
Pharmaceutical
The USA has completed its withdrawal from the World Health Organization (WHO), according to a joint announcement by the US Department of Health and Human Services (HHS) and the US Department of State. The statement frames the move in overtly political terms, accusing the WHO of pandemic mismanagement and undue influence by member states. 23 January 2026
Generics
The Russian government has extended the permit for domestic pharmaceutical companies Promomed and PSK Pharma to produce generics of Ozempic (semaglutide). It is reported, future production will be carried out without the consent of the right holder – the Danish pharmaceutical major Novo Nordisk, reports The Pharma Letter’s local correspondent. 23 January 2026
Biotechnology
US healthcare company Sagebrush Health Services, a non-profit organization serving more than 10,000 Nevada patients, has filed a lawsuit against Amgen. 22 January 2026
Pharmaceutical
Congressional negotiators released a more than 1,000 page bipartisan government funding bill on Tuesday, racing a shutdown deadline of 30 January and aiming to avoid another lapse after last fall’s lengthy shutd 21 January 2026
Pharmaceutical
The Hellenic Association of Pharmaceutical Companies (SFEE) said Greece’s medicines funding model is drifting further out of balance, pushing up mandatory rebates and clawback payments and, in its telling, risking poorer access to new drugs. 19 January 2026
Pharmaceutical
What started as a pan-African treaty push is now a staffed regulator with a Kigali address and early procedures already being tested. The African Medicines Agency (AMA) was adopted by the African Union in 2019 and its treaty entered into force in 2021. By 2026, 31 countries had ratified it. Rwanda hosts AMA’s headquarters in Kigali, which became operational in late 2024. 15 January 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze